102 Publications (Page 1 of 5)
2021
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence
Nguyen, Ryan HNguyen, Ryan HVater, Laura BVater, Laura BTimsina, Lava RTimsina, Lava RDurm, Gregory ADurm, Gregory ARupp, KatelinRupp, KatelinWright, KeyleeWright, KeyleeSpitznagle, Miranda HSpitznagle, Miranda HBrandy, PaulBrandy, PaulJalal, Shadia IJalal, Shadia ICarter-Harris, LisaCarter-Harris, LisaHudmon, Karen SHudmon, Karen SHanna, Nasser HHanna, Nasser HLoehrer, Patrick JLoehrer, Patrick JCeppa, DuyKhanh P and Ceppa, DuyKhanh P
PLoS One, vol. 16, (no. 4), Apr 2021. | Journal Article
2020
An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function
Ramchandani, Neal KRamchandani, Neal KKesler, Kenneth AKesler, Kenneth ARogers, Jonathon DRogers, Jonathon DValsangkar, NakulValsangkar, NakulStokes, Samatha MStokes, Samatha MJalal, Shadia I and Jalal, Shadia I
Journal of visualized experiments : JoVE, (no. 158), 2020-Apr-17. | Journal Article
 
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179
Durm, Greg ADurm, Greg ADurm, Greg ADurm, Greg ADurm, Greg AJabbour, Salma KJabbour, Salma KJabbour, Salma KJabbour, Salma KJabbour, Salma KAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KAlthouse, Sandra KLiu, ZiyueLiu, ZiyueLiu, ZiyueLiu, ZiyueLiu, ZiyueSadiq, Ahad ASadiq, Ahad ASadiq, Ahad ASadiq, Ahad ASadiq, Ahad AZon, Robin TZon, Robin TZon, Robin TZon, Robin TZon, Robin TJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HKloecker, Goetz HWilliamson, Michael JWilliamson, Michael JWilliamson, Michael JWilliamson, Michael JWilliamson, Michael JReckamp, Karen LReckamp, Karen LReckamp, Karen LReckamp, Karen LReckamp, Karen LLangdon, Robert MLangdon, Robert MLangdon, Robert MLangdon, Robert MLangdon, Robert MKio, Ebenezer AKio, Ebenezer AKio, Ebenezer AKio, Ebenezer AKio, Ebenezer AGentzler, Ryan DGentzler, Ryan DGentzler, Ryan DGentzler, Ryan DGentzler, Ryan DAdesunloye, Bamidele AAdesunloye, Bamidele AAdesunloye, Bamidele AAdesunloye, Bamidele AAdesunloye, Bamidele AHarb, Wael AHarb, Wael AHarb, Wael AHarb, Wael AHarb, Wael AWalling, Radhika VWalling, Radhika VWalling, Radhika VWalling, Radhika VWalling, Radhika VTitzer, Michael LTitzer, Michael LTitzer, Michael LTitzer, Michael LTitzer, Michael LHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser H and Hanna, Nasser H
Cancer, vol. 126, (no. 19), pp. 4353-4361, Oct 2020. | Journal Article
 
A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: A Big Ten Cancer Research Consortium study
Mamdani, HirvaMamdani, HirvaMehta, RutikaMehta, RutikaFountzilas, ChristosFountzilas, ChristosRadovich, MilanRadovich, MilanPerkins, SusanPerkins, SusanJalal, Shadia Ibrahim and Jalal, Shadia Ibrahim
Journal of Clinical Oncology, vol. 38, (no. 4_suppl), pp. TPS472, 2020-02-01. | Journal Article
 
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Chung, Hyun CheolPiha-Paul, Sarina ALopez-Martin, JoseSchellens, Jan H.MKao, StevenMiller, Wilson HDelord, Jean-PierreGao, BoPlanchard, DavidGottfried, MayaZer, AlonaJalal, Shadia IPenel, NicolasMehnert, Janice MMatos, IgnacioBennouna, JaafarKim, Dong-WanXu, LeiKrishnan, SubaNorwood, Kevin and Ott, Patrick A
Journal of Thoracic Oncology, vol. 15, (no. 4), pp. 627, April 2020. | Journal Article
 
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Voss, Martin HGordon, Michael SMita, MonicaRini, BrianMakker, VickyMacarulla, TeresaSmith, David CCervantes, AndrésPuzanov, IgorPili, RobertoWang, DingJalal, ShadiaPant, ShubhamPatel, Manish RNeuwirth, Rachel LEnke, AaronShou, YapingSedarati, FarhadFaller, Douglas V and Burris, Howard A
British journal of cancer, September 11, 2020. | Journal Article
 
Phase II study of the combination of abemaciclib and pembrolizumab in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Uboha, Nataliya VolodymyrivnaEickhoff, Jens CChandrasekharan, ChandrikhaJalal, Shadia IbrahimBenson, Al BowenDeming, Dustin ALindemann, Stephen and Hochster, Howard S
Journal of Clinical Oncology, vol. 38, (no. 4_suppl), pp. TPS461, 2020-02-01. | Journal Article
 
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study
Mamdani, HirvaMamdani, HirvaMamdani, HirvaMamdani, HirvaMamdani, HirvaSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JKasi, Pashtoon MurtazaKasi, Pashtoon MurtazaKasi, Pashtoon MurtazaKasi, Pashtoon MurtazaKasi, Pashtoon MurtazaAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JKesler, KennethKesler, KennethKesler, KennethKesler, KennethKesler, KennethBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherPerkins, SusanPerkins, SusanPerkins, SusanPerkins, SusanPerkins, SusanJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia Ibrahim and Jalal, Shadia Ibrahim
Journal of Clinical Oncology, vol. 38, (no. 4_suppl), pp. 404, 2020-02-01. | Journal Article
 
The Case for Maintenance Pemetrexed Plus Bevacizumab
Hanna, NasserHanna, NasserJalal, Shadia and Jalal, Shadia
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 38, (no. 7), pp. 771, 2020-Mar-01. | Journal Article
2019
Acceptance and Commitment Therapy for Symptom Interference in Advanced Lung Cancer and Caregiver Distress: A Pilot Randomized Trial
Mosher, Catherine EMosher, Catherine EMosher, Catherine EMosher, Catherine EMosher, Catherine EMosher, Catherine EMosher, Catherine EMosher, Catherine ESecinti, EkinSecinti, EkinSecinti, EkinSecinti, EkinSecinti, EkinSecinti, EkinSecinti, EkinSecinti, EkinHirsh, Adam THirsh, Adam THirsh, Adam THirsh, Adam THirsh, Adam THirsh, Adam THirsh, Adam THirsh, Adam THanna, NasserHanna, NasserHanna, NasserHanna, NasserHanna, NasserHanna, NasserHanna, NasserHanna, NasserEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HEinhorn, Lawrence HJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IJalal, Shadia IDurm, GregoryDurm, GregoryDurm, GregoryDurm, GregoryDurm, GregoryDurm, GregoryDurm, GregoryDurm, GregoryChampion, Victoria LChampion, Victoria LChampion, Victoria LChampion, Victoria LChampion, Victoria LChampion, Victoria LChampion, Victoria LChampion, Victoria LJohns, Shelley AJohns, Shelley AJohns, Shelley AJohns, Shelley AJohns, Shelley AJohns, Shelley AJohns, Shelley A and Johns, Shelley A
Journal of Pain and Symptom Management, vol. 58, (no. 4), Oct 2019. | Journal Article
 
A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
Sharman, Jeffrey PSharman, Jeffrey PSharman, Jeffrey PWheler, JenniferWheler, Jennifer JWheler, JenniferEinhorn, LawrenceEinhorn, LawrenceEinhorn, LawrenceDowlati, AfshinDowlati, AfshinDowlati, AfshinShapiro, GeoffreyShapiro, GeoffreyShapiro, Geoffrey IHilton, JohnHilton, JohnHilton, JohnBurke, John MBurke, John MBurke, John MSiddiqi, TanyaSiddiqi, TanyaSiddiqi, TanyaWhiting, NancyWhiting, NancyWhiting, NancyJalal, ShadiaJalal, Shadia I and Jalal, Shadia
Investigational New Drugs, vol. 37, (no. 4), pp. 747, 20190815. | Journal Article
 
Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors
Mamdani, Hirva and Jalal, Shadia I
Annals of Translational Medicine, vol. 7, (no. S3), pp. S155, 2019-07-00. | Journal Article
 
DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC)
Mamdani, HirvaChen, JerryKim, SeonghoIbrahim, YahyaAsad, Mohammad Fahad BinNieva, Jorge JFeldman, RebeccaNaqash, Abdul RafehLiu, Stephen VMa, Patrick CPortnoy, David CraigBorghaei, HosseinAbdel Karim, Nagla FawzyBoumber, YanisVanderwalde, Ari MSpira, Alexander I and Jalal, Shadia Ibrahim
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 9100, 2019-05-20. | Journal Article
 
Doppler fluctuation spectroscopy of intracellular dynamics in living tissue
Li, ZheLi, ZheSun, HaoSun, HaoTurek, JohnTurek, JohnJalal, ShadiaJalal, ShadiaChildress, MichaelChildress, MichaelNolte, David D and Nolte, David D
Journal of the Optical Society of America. A, Optics, image science, and vision, vol. 36, (no. 4), pp. 677, 2019-Apr-01. | Journal Article
 
Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059
Wainberg, Zev AWainberg, Zev AYoon, Harry HYoon, Harry HCatenacci, Daniel V.TCatenacci, Daniel V.TJalal, Shadia IbrahimJalal, Shadia IbrahimMuro, KeiMuro, KeiGarrido, MarceloGarrido, MarceloGolan, TaliaGolan, TaliaDoi, ToshihikoDoi, ToshihikoGeva, RavitGeva, RavitKu, Geoffrey YuyatKu, Geoffrey YuyatBleeker, Jonathan ScottBleeker, Jonathan ScottBang, Yung-JueBang, Yung-JueHara, HirokiHara, HirokiChung, Hyun CheolChung, Hyun CheolWang, Jiang DianWang, Jiang DianHazzard, AndreaHazzard, AndreaShah, SukrutShah, SukrutFuchs, Charles S and Fuchs, Charles S
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 4009, 2019-05-20. | Journal Article
 
Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence
Nguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanNguyen, RyanVater, LauraVater, LauraVater, LauraVater, LauraVater, LauraVater, LauraVater, LauraTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RTimsina, Lava RDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewDurm, Greg AndrewRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinRupp, KatelinWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeWright, KeyleeSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaSpitznagle, MirandaPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyPaul, BrandyJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaCarter-Harris, LisaHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHudmon, Karen SHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HHanna, Nasser HLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JLoehrer, Patrick JCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanhCeppa, DuyKhanh and Ceppa, DuyKhanh
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 6578, 2019-05-20. | Journal Article
 
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yoon-Koo, KangCatenacci, Daniel VMuro, KeiFuchs, Charles SGeva, RavitHara, HirokiGolan, TaliaGarrido, MarceloJalal, Shadia IBorg, ChristopheDoi, ToshihikoYoon, Harry HSavage, Mary JWang, JiangdianDalal, Rita PShah, SukrutWainberg, Zev A and Chung, Hyun C
Gastric Cancer, vol. 22, (no. 4), pp. 828-837, 2019. | Journal Article
 
Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H
Gubens, Matthew ASequist, Lecia VStevenson, James PPowell, Steven FVillaruz, Liza CGadgeel, Shirish MLanger, Corey JPatnaik, AmitaBorghaei, HosseinJalal, Shadia IFiore, JosephSaraf, SanatanRaftopoulos, Harry and Gandhi, Leena
Lung Cancer, vol. 130, pp. 66, April 2019. | Journal Article
 
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from Big Ten Cancer Research Consortium study
Mamdani, HirvaMamdani, HirvaMamdani, HirvaMamdani, HirvaMamdani, HirvaSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JKesler, KennethKesler, KennethKesler, KennethKesler, KennethKesler, KennethBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherPerkins, Susan MPerkins, Susan MPerkins, Susan MPerkins, Susan MPerkins, Susan MJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia Ibrahim and Jalal, Shadia Ibrahim
Journal of Clinical Oncology, vol. 37, (no. 15_suppl), pp. 4058, 2019-05-20. | Journal Article
 
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study
Mamdani, HirvaMamdani, HirvaMamdani, HirvaMamdani, HirvaMamdani, HirvaSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JSchneider, Bryan JAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IAbushahin, Laith IBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JBirdas, Thomas JKesler, KennethKesler, KennethKesler, KennethKesler, KennethKesler, KennethLee, AhranLee, AhranLee, AhranLee, AhranLee, AhranBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherBurney, HeatherPerkins, SusanPerkins, SusanPerkins, SusanPerkins, SusanPerkins, SusanJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia IbrahimJalal, Shadia Ibrahim and Jalal, Shadia Ibrahim
Journal of Clinical Oncology, vol. 37, (no. 4_suppl), pp. 5, 2019-02-01. | Journal Article
2018
24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Borghaei, HosseinLanger, Corey JGadgeel, ShirishPapadimitrakopoulou, Vassiliki APatnaik, AmitaPowell, Steven FGentzler, Ryan DMartins, Renato GStevenson, James PJalal, Shadia IPanwalkar, AmitChih-Hsin Yang, JamesGubens, MatthewSequist, Lecia VAwad, Mark MFiore, JosephSaraf, SanatanKeller, Steven and Gandhi, Leena
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, August 20, 2018. | Journal Article
 
24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed-carboplatin plus pembrolizumab as first-line therapy for advanced nonsquamous NSCLC
Gentzler, Ryan DGentzler, Ryan DLanger, Corey JLanger, Corey JBorghaei, HosseinBorghaei, HosseinGadgeel, Shirish MGadgeel, Shirish MPapadimitrakopoulou, VassilikiPapadimitrakopoulou, VassilikiPatnaik, AmitaPatnaik, AmitaPowell, Steven FrancisPowell, Steven FrancisMartins, Renato GMartins, Renato GStevenson, JamesStevenson, JamesJalal, Shadia IbrahimJalal, Shadia IbrahimPanwalkar, Amit WPanwalkar, Amit WYang, James Chih-HsinYang, James Chih-HsinGubens, Matthew AGubens, Matthew ASequist, Lecia VSequist, Lecia VAwad, Mark MAwad, Mark MFiore, JosephFiore, JosephSaraf, SanatanSaraf, SanatanKeller, Steven MKeller, Steven MGandhi, Leena and Gandhi, Leena
Journal of Clinical Oncology, vol. 36, (no. 15_suppl), pp. 9026, 2018-05-20. | Journal Article
 
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b Study
Kim, Edward SKelly, KarenPaz-Ares, LuisGarrido, PilarJalal, ShadiaMahadevan, DarukaGuttierrez, Martin AProvencio, MarianoSchaefer, EricShaheen, MontaserJohnston, Erica LTurner, P KellieKambhampati, Siva Rama PBeckmann, RichardHossain, AnwarJohn, William J and Goldman, Jonathan W
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-Aug-06. | Journal Article
 
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study
Kim, EdwardKelly, KarenPaz-Ares, LuisGarrido, PilarJalal, ShadiaMahadevan, DarukaGutierrez, MartinProvencio, MarianoSchaefer, EricShaheen, MonteJohnston, EricaTurner, PKambhampati, SivaBeckmann, RichardHossain, AnwarJohn, William and Goldman, Jonathan
2018-11-01. | Journal Article
 
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study
Kim, Edward SKelly, KarenPaz-Ares, Luis GGarrido, PilarJalal, ShadiaMahadevan, DarukaGutierrez, MartinProvencio, MarianoSchaefer, EricShaheen, MonteJohnston, Erica LTurner, P. KellieKambhampati, Siva Rama PrasadBeckmann, RichardHossain, AnwarJohn, William J and Goldman, Jonathan W
Clinical Cancer Research, vol. 24, (no. 22), pp. 5551, 2018-11-15. | Journal Article